stockportfolio.pro
Eton Pharmaceuticals, Inc. (ETON)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Eton Pharmaceuticals, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $959,000 | $39,000 | $21.83M | $21.25M | $31.64M | $39.01M | $79.95M |
| Gross profit | — | $506,000 | $-397,000 | $19.00M | $14.32M | $21.06M | $23.41M | $42.74M |
| Net income | $-12.74M | $-18.32M | $-27.97M | $-1.96M | $-9.02M | $-936,000 | $-3.82M | $-4.60M |
| Net margin | — | -1910.3% | -71717.9% | -9.0% | -42.4% | -3.0% | -9.8% | -5.8% |
Source: Eton Pharmaceuticals, Inc. SEC filings (10-K).
What growth is priced into ETON stock?
At today's market cap of $886.42M, Eton Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 27.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $10.19M from the FY ending 2025-12-31). For comparison, revenue 359.6%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 8 years of Eton Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ETON in your portfolio →
Eton Pharmaceuticals, Inc. financial history by metric
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Eton Pharmaceuticals, Inc. — frequently asked questions
What is Eton Pharmaceuticals, Inc.'s revenue?
Eton Pharmaceuticals, Inc. (ETON) reported revenue of $79.95M for fiscal year 2025, up 104.9% from the prior year, according to its SEC filings.
Is Eton Pharmaceuticals, Inc. profitable?
No — ETON reported a net loss of $-4.60M in fiscal 2025.
What is ETON's P/E ratio?
Eton Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Eton Pharmaceuticals, Inc. growing?
ETON's revenue grew at roughly 359.6% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Eton Pharmaceuticals, Inc. have?
As of fiscal year 2025, ETON carried roughly $30.56M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Eton Pharmaceuticals, Inc.'s gross margin?
ETON's gross margin was 53.5% in fiscal 2025 — gross profit of $42.74M on revenue of $79.95M.
What is Eton Pharmaceuticals, Inc.'s market cap?
Eton Pharmaceuticals, Inc. (ETON) has a market capitalization of about $886.42M, based on the latest data in our nightly-refreshed cache.
When does Eton Pharmaceuticals, Inc.'s fiscal year end?
ETON's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ETON stock?
At today's market cap of $886.42M, Eton Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 27.9% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $10.19M from the FY ending 2025-12-31). For comparison, revenue 359.6%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Eton Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.